Context Therapeutics

CNTX

Market cap $117M

1.27 USD

+0.12

10.43%

At close Updated Dec 19, 4:00 PM EST

Pre-market

After hours

1.24

-0.03

2.36%

1 day

10.43%

5 days

20.95%

1 month

8.55%

3 months

31.17%

6 months

121.8%

Year to date

6.72%

1 year

16.51%

5 years

-75.1%

10 years

-75.1%

About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Employees: 9

Healthcare Biotechnology